Primary Immune Deficiency (PID) - Pipeline Review, H2 2015 - PowerPoint PPT Presentation

Loading...

PPT – Primary Immune Deficiency (PID) - Pipeline Review, H2 2015 PowerPoint presentation | free to download - id: 7fa667-MTM3O



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Primary Immune Deficiency (PID) - Pipeline Review, H2 2015

Description:

Research Beam added a report on “Primary Immune Deficiency (PID) - Pipeline Review, H2 2015” Enquiry about report: – PowerPoint PPT presentation

Number of Views:12

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Primary Immune Deficiency (PID) - Pipeline Review, H2 2015


1
Primary Immune Deficiency (PID) - Pipeline
Review, H2 2015
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022 E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview
  • Scope
  • The report provides a snapshot of the global
    therapeutic landscape of Primary Immune
    Deficiency (PID)
  • The report reviews key pipeline products under
    drug profile section which includes, product
    description, MoA and RD brief, licensing and
    collaboration details other developmental
    activities
  • The report reviews key players involved in the
    therapeutics development for Primary Immune
    Deficiency (PID) and enlists all their major and
    minor projects
  • The report summarizes all the dormant and
    discontinued pipeline projects
  • A review of the Primary Immune Deficiency (PID)
    products under development by companies and
    universities/research institutes based on
    information derived from company and
    industry-specific sources
  • Pipeline products coverage based on various
    stages of development ranging from
    pre-registration till discovery and undisclosed
    stages
  • A detailed assessment of monotherapy and
    combination therapy pipeline projects
  • Coverage of the Primary Immune Deficiency (PID)
    pipeline on the basis of target, MoA, route of
    administration and molecule type
  • Latest news and deals relating related to
    pipeline products
  • Read More At http//www.researchbeam.com/primary
    -immune-deficiency-pid-pipeline-review-h2-2015-mar
    ket

3


Table of Content
List of Figures Number of Products under
Development for Primary Immune Deficiency (PID),
H2 2015 9 Number of Products under Development
for Primary Immune Deficiency (PID) - Comparative
Analysis, H2 2015 10 Number of Products under
Development by Companies, H2 2015 11 Number of
Products under Investigation by
Universities/Institutes, H2 2015 12 Comparative
Analysis by Late Stage Development, H2 2015
13 Comparative Analysis by Clinical Stage
Development, H2 2015 14 Assessment by Monotherapy
Products, H2 2015 29 Assessment by Combination
Products, H2 2015 30 Number of Products by
Targets, H2 2015 31 Number of Products by Stage
and Targets, H2 2015 31 Number of Products by
Mechanism of Actions, H2 2015 33 Number of
Products by Stage and Mechanism of Actions, H2
2015 33 Number of Products by Routes of
Administration, H2 2015 35 Number of Products by
Stage and Routes of Administration, H2 2015
35 Number of Products by Molecule Types, H2 2015
37 Number of Products by Stage and Top 10
Molecule Types, H2 2015 37
4


Report Overview
Reasons to buy Provides strategically
significant competitor information, analysis, and
insights to formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for Primary Immune Deficiency (PID) Plan mergers
and acquisitions effectively by identifying key
players of the most promising pipeline Devise
corrective measures for pipeline projects by
understanding Primary Immune Deficiency (PID)
pipeline depth and focus of Indication
therapeutics Develop and design in-licensing and
out-licensing strategies by identifying
prospective partners with the most attractive
projects to enhance and expand business potential
and Scope Modify the therapeutic portfolio by
identifying discontinued projects and
understanding the factors that drove them from
pipeline Enquire At http//www.researchbeam.co
m/primary-immune-deficiency-pid-pipeline-review-h2
-2015-market/enquire-about-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/primary-immune-deficie
ncy-pid-pipeline-review-h2-2015-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022 E-MAIL sales_at_researchbeam.com
About PowerShow.com